On the other hand, the novel aspect of this study relates to the study population: most of the studies in the existing literature analyzed groups of people with metabolic disorders (e.g., obesity and diabetes) and assessed adiponectin at baseline and after a period of follow-up, predominantly investigating adiponectin in association with metabolic disorders. Here, ADIPOQ is linked to Obesity.